AGF Management Ltd. Buys 2,247 Shares of Elevance Health, Inc. $ELV

by · The Cerbat Gem

AGF Management Ltd. grew its position in shares of Elevance Health, Inc. (NYSE:ELV – Free Report) by 21.8% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 12,539 shares of the company’s stock after buying an additional 2,247 shares during the quarter. AGF Management Ltd.’s holdings in Elevance Health were worth $4,052,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also bought and sold shares of the company. Vermillion & White Wealth Management Group LLC boosted its holdings in shares of Elevance Health by 94.9% in the second quarter. Vermillion & White Wealth Management Group LLC now owns 76 shares of the company’s stock worth $30,000 after buying an additional 37 shares during the last quarter. BOK Financial Private Wealth Inc. purchased a new position in shares of Elevance Health during the 2nd quarter worth $32,000. Activest Wealth Management lifted its position in Elevance Health by 66.7% during the third quarter. Activest Wealth Management now owns 85 shares of the company’s stock valued at $27,000 after purchasing an additional 34 shares in the last quarter. Glass Jacobson Investment Advisors llc lifted its position in shares of Elevance Health by 400.0% during the 2nd quarter. Glass Jacobson Investment Advisors llc now owns 100 shares of the company’s stock valued at $39,000 after buying an additional 80 shares in the last quarter. Finally, Motco lifted its holdings in Elevance Health by 334.8% during the third quarter. Motco now owns 100 shares of the company’s stock valued at $32,000 after purchasing an additional 77 shares in the last quarter. 89.24% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the stock. JPMorgan Chase & Co. upped their target price on shares of Elevance Health from $394.00 to $397.00 and gave the stock an “overweight” rating in a report on Monday. Mizuho set a $413.00 target price on Elevance Health in a research report on Friday, January 9th. Bank of America lifted their price target on Elevance Health from $330.00 to $370.00 and gave the stock a “neutral” rating in a research report on Friday, October 10th. Wall Street Zen raised shares of Elevance Health from a “hold” rating to a “buy” rating in a research note on Saturday. Finally, The Goldman Sachs Group began coverage on Elevance Health in a research note on Tuesday, October 14th. They set a “neutral” rating and a $343.00 target price on the stock. Twelve analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $390.55.

View Our Latest Stock Analysis on ELV

Elevance Health Trading Down 0.9%

Shares of NYSE ELV opened at $338.66 on Wednesday. The stock has a market capitalization of $75.26 billion, a P/E ratio of 13.48, a price-to-earnings-growth ratio of 1.90 and a beta of 0.50. The business has a fifty day moving average price of $351.99 and a 200 day moving average price of $329.59. Elevance Health, Inc. has a 1-year low of $273.71 and a 1-year high of $458.75. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.54 and a quick ratio of 1.56.

Elevance Health (NYSE:ELV – Get Free Report) last issued its quarterly earnings data on Wednesday, January 28th. The company reported $3.33 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.10 by $0.23. The firm had revenue of $49.31 billion for the quarter, compared to the consensus estimate of $49.52 billion. Elevance Health had a net margin of 2.84% and a return on equity of 15.59%. The company’s quarterly revenue was up 9.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.84 EPS. Elevance Health has set its FY 2026 guidance at 25.500- EPS. Equities research analysts expect that Elevance Health, Inc. will post 33.96 EPS for the current fiscal year.

Elevance Health Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, March 25th. Shareholders of record on Tuesday, March 10th will be issued a $1.72 dividend. This is a boost from Elevance Health’s previous quarterly dividend of $1.71. This represents a $6.88 annualized dividend and a yield of 2.0%. The ex-dividend date of this dividend is Tuesday, March 10th. Elevance Health’s dividend payout ratio is 27.23%.

Elevance Health News Roundup

Here are the key news stories impacting Elevance Health this week:

  • Positive Sentiment: JPMorgan raised its price target slightly from $394 to $397 and maintained an “overweight” rating, which supports upside vs. the current price. Read More.
  • Neutral Sentiment: Options-market activity is drawing attention — some traders see positioning that could presage larger moves, but this is speculative and not a direct fundamental change. Read More.
  • Neutral Sentiment: Seeking Alpha published a long-form take (“It Has Been Painful, But This Too Shall Pass”) arguing the near-term weakness is cyclical and could reverse — useful for longer-term investors but less likely to move stock intraday. Read More.
  • Neutral Sentiment: The Globe and Mail aggregated analyst commentary on multiple healthcare names including Elevance; helpful context but no single decisive call. Read More.
  • Negative Sentiment: RBC downgraded ELV from “outperform” to “sector perform” and set a $358 target — a downgrade in stance that likely pressured sentiment despite a modestly positive target. Read More.
  • Negative Sentiment: Truist trimmed its price target from $400 to $390 while keeping a “buy” rating — the lower target reduces upside expectations and can weigh on the stock. Read More.
  • Negative Sentiment: Jefferies cut its price target to $395, another downward revision that adds to the negative analyst tone. Read More.
  • Negative Sentiment: Sanford C. Bernstein lowered its target to $409 — still above the current price but a cut nonetheless, contributing to the cluster of downward revisions. Read More.

About Elevance Health

(Free Report)

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.

Featured Articles

Want to see what other hedge funds are holding ELV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elevance Health, Inc. (NYSE:ELV – Free Report).